NEUROLOGICAL DISORDERS IN HEMATOLOGICAL MALIGNANCIES: A COMPARATIVE ANALYSIS
Keywords:
: opioid, neuropsychological changes, cognitive disorder, emotional disorder, addiction, rehabilitationAbstract
Objective: To study the frequency and characteristics of neurological disorders in patients with various hematological malignancies. Materials and Methods: A prospective study was conducted involving 111 patients with hematological malignancies: acute lymphoblastic leukemia (ALL, n=64), acute myeloid leukemia (AML, n=28), and lymphoma (n=19). Cognitive impairment, attention deficit, headache, peripheral neuropathy, movement coordination disorders, and autonomic dystonia were assessed. Results: Cognitive impairment was significantly more common in patients with ALL (63.5±6.2%) compared to AML (57.1±8.6%) and lymphoma (38.5±14.6%) (p<0.001). Other neurological manifestations did not demonstrate statistically significant differences between the groups (p>0.05). Conclusion: Patients with ALL have the highest risk of developing cognitive impairment, which requires special consideration when planning therapeutic and rehabilitation measures.
References
Dropcho EJ. Neurotoxicity of cancer chemotherapy. Semin Neurol. 2010;30(3):273-286. doi:10.1055/s-0030-1255217
Taillibert S, Chamberlain MC. Chemotherapy-related neurotoxicity. Curr Neurol Neurosci Rep. 2011;11(1):48-54. doi:10.1007/s11910-010-0147-9
Graus F, Dalmau J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2019;16(9):535-548. doi:10.1038/s41571-019-0194-4
Pruitt AA. Neurologic complications of hematopoietic cell transplantation. Neurol Clin. 2010;28(4):1097-1112. doi:10.1016/j.ncl.2010.03.021
Vezmar S, Becker A, Bode U, Jaehde U. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy. 2003;49(1-2):92-104. doi:10.1159/000069773
Hwang TL, Yung WK, Estey EH, Fields WS. Central nervous system toxicity with high-dose Ara-C. Neurology. 1985;35(9):1475-1479. doi:10.1212/wnl.35.10.1475
Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012;14 Suppl 4:iv45-iv54. doi:10.1093/neuonc/nos203
Merchant TE, Pollack IF, Loeffler JS. Brain tumors across the age spectrum: biology, therapy, and late effects. Semin Radiat Oncol. 2010;20(1):58-66. doi:10.1016/j.semradonc.2009.09.005
Siegal D, Keller A, Xu W, et al. Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance. Biol Blood Marrow Transplant. 2007;13(10):1369-1379. doi:10.1016/j.bbmt.2007.07.013
Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541-1552. doi:10.1056/NEJMra1400972
Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin. 2015;65(2):123-138. doi:10.3322/caac.21258
Krull KR, Brinkman TM, Li C, et al. Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study. J Clin Oncol. 2013;31(35):4407-4415. doi:10.1200/JCO.2012.48.2315
Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014;155(12):2461-2470. doi:10.1016/j.pain.2014.09.020
Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(28):3325-3348. doi:10.1200/JCO.20.01399
